Overall, this study identified that AhR activation drives abnormal erythrocyte and PLT differentiation in individuals with cancer, and targeting the Kyn–AhR pathway could be explored to treat anemia and thrombocytosis in individuals with cancer. This evidence concerns the gene AHR and cancer.